Cargando…

A systematic quality rating of available mobile health apps for borderline personality disorder

BACKGROUND: Mobile health apps (MHAs) may offer a mean to overcome treatment barriers in Borderline Personality Disorder (BPD) mental health care. However, MHAs for BPD on the market lack transparency and quality assessment. METHODS: European app stores were systematically searched, and two independ...

Descripción completa

Detalles Bibliográficos
Autores principales: Steubl, Lena Sophia, Reimann, Josephin, Simon, Laura, Terhorst, Yannik, Stach, Michael, Baumeister, Harald, Sander, Lasse Bosse, Messner, Eva-Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9158356/
https://www.ncbi.nlm.nih.gov/pubmed/35642024
http://dx.doi.org/10.1186/s40479-022-00186-w
Descripción
Sumario:BACKGROUND: Mobile health apps (MHAs) may offer a mean to overcome treatment barriers in Borderline Personality Disorder (BPD) mental health care. However, MHAs for BPD on the market lack transparency and quality assessment. METHODS: European app stores were systematically searched, and two independent trained reviewers extracted relevant MHAs. Employed methods and privacy and security details documentation of included MHAs were extracted. MHAs were then assessed and rated using the German version of the standardized Mobile Application Rating Scale (MARS-G). Mean values and standard deviations of all subscales (engagement, functionality, aesthetics, information, and therapeutic gain) and correlations with user ratings were calculated. RESULTS: Of 2977 identified MHAs, 16 were included, showing average quality across the four main subscales (M = 3.25, SD = 0.68). Shortcomings were observed with regard to engagement (M = 2.87, SD = 0.99), potential therapeutic gain (M = 2.67, SD = 0.83), existing evidence base (25.0% of included MHAs were tested empirically), and documented privacy and security details. No significant correlations were found between user ratings and the overall total score of the MARS-G or MARS-G main subscales. CONCLUSIONS: Available MHAs for BPD vary in quality and evidence on their efficacy, effectiveness, and possible adverse events is scarce. More substantial efforts to ensure the quality of MHAs available for patients and a focus on transparency, particularly regarding privacy and security documentation, are necessary. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40479-022-00186-w.